marketcap
Facebook
Twitter
Telegram
Report an ErrorAnnual report 2024
added 10-25-2025
Kamada Ltd. Cash and Cash Equivalents 2011-2025 | KMDA
Annual Cash and Cash Equivalents Kamada Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 78.4 M | 55.6 M | 34.3 M | 18.6 M | 70.2 M | 42.7 M | 18.1 M | 12.7 M | 9.97 M | 5.05 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 78.4 M | 5.05 M | 34.6 M |
Quarterly Cash and Cash Equivalents Kamada Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 18.6 M | 99.8 M | 68.4 M | - | 70.2 M | 52.5 M | 57.4 M | - | 42.7 M | - | - | - | 18.1 M | - | - | - | 12.7 M | - | - | - | 9.97 M | - | - | - | 5.05 M | - | - | - | 14.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 99.8 M | 5.05 M | 39.2 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Graybug Vision
GRAY
|
5.53 M | $ 0.44 | -11.23 % | $ 9.65 M |  USA |
 |
AgeX Therapeutics
AGE
|
345 K | $ 11.3 | -10.17 % | $ 12.2 K | - |
 |
Galera Therapeutics
GRTX
|
8.29 M | $ 0.14 | -32.59 % | $ 7.61 M | USA |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
3.02 M | $ 4.37 | -1.58 % | $ 28.1 M |  China |
 |
Axon Enterprise
AXON
|
455 M | $ 755.0 | 0.8 % | $ 57.2 B | USA |
 |
Caladrius Biosciences
CLBS
|
16.2 M | $ 0.43 | -16.75 % | $ 25.8 M | USA |
 |
Sorrento Therapeutics
SRNE
|
36.7 M | $ 0.27 | -29.58 % | $ 126 M | USA |
 |
BeiGene, Ltd.
BGNE
|
2.63 B | $ 184.71 | 0.49 % | $ 251 B |  Cayman-islands |
 |
ContraFect Corporation
CFRX
|
8.91 M | $ 1.47 | -5.16 % | $ 5.39 M | USA |
 |
Orchard Therapeutics plc
ORTX
|
68.4 M | $ 4.93 | 1.02 % | $ 90.8 M |  Britain |
 |
Midatech Pharma plc
MTP
|
1.67 M | $ 0.29 | -18.52 % | $ 27.3 M | Britain |
 |
Advaxis
ADXS
|
4.88 M | $ 0.31 | -9.65 % | $ 45.9 M | USA |
 |
La Jolla Pharmaceutical Company
LJPC
|
46.7 M | $ 6.2 | - | $ 154 M | USA |
 |
Zymeworks
ZYME
|
202 M | $ 6.42 | - | $ 404 M |  Canada |
 |
Aeterna Zentaris
AEZS
|
16.4 M | $ 5.72 | 5.93 % | $ 314 M | Canada |
 |
Checkmate Pharmaceuticals
CMPI
|
50.7 M | $ 10.5 | - | $ 231 M | USA |
 |
BioDelivery Sciences International
BDSI
|
112 M | $ 2.58 | -4.8 % | $ 255 M | USA |
 |
Mesoblast Limited
MESO
|
60.4 M | $ 16.73 | 0.12 % | $ 10.9 B |  Australia |
 |
Zosano Pharma Corporation
ZSAN
|
11 M | $ 0.56 | 7.23 % | $ 2.72 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.41 M | $ 0.5 | - | $ 7.46 M |  Israel |
 |
Kiromic BioPharma
KRBP
|
1.14 M | $ 3.15 | 6.61 % | $ 3.08 M | USA |
 |
Moderna
MRNA
|
1.93 B | $ 25.35 | -4.91 % | $ 9.73 B | USA |
 |
Albireo Pharma
ALBO
|
248 M | $ 44.15 | -0.23 % | $ 916 M | USA |
 |
Merus N.V.
MRUS
|
293 M | $ 94.9 | 0.32 % | $ 6.09 B |  Niderland |
 |
Stealth BioTherapeutics Corp
MITO
|
32.8 M | $ 0.32 | - | $ 23.9 M | USA |
 |
Kaleido Biosciences
KLDO
|
46.2 M | $ 0.29 | -3.69 % | $ 12.4 M | USA |
 |
Entasis Therapeutics Holdings
ETTX
|
32.3 M | $ 2.19 | - | $ 105 M | USA |
 |
Humanigen
HGEN
|
10.2 M | $ 0.04 | -81.12 % | $ 4.28 M | USA |
 |
Aptinyx
APTX
|
56.2 M | $ 0.06 | -39.0 % | $ 4.57 M | USA |
 |
Tyme Technologies
TYME
|
108 M | $ 0.31 | 8.07 % | $ 54 M | USA |
 |
Forward Pharma A/S
FWP
|
70.8 M | $ 2.64 | -0.75 % | $ 18.7 M |  Danmark |
 |
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | $ 0.39 | - | $ 26.5 M | USA |
 |
Celyad Oncology SA
CYAD
|
12.4 M | $ 0.47 | - | $ 12.5 M |  Belgium |
 |
Nektar Therapeutics
NKTR
|
35.3 M | $ 60.92 | -2.64 % | $ 11.6 B | USA |
 |
Brickell Biotech
BBI
|
10.9 M | $ 2.11 | -5.38 % | $ 6.06 M | USA |
 |
Genocea Biosciences
GNCA
|
37.1 M | $ 0.05 | -15.0 % | $ 3.04 M | USA |
 |
Codiak BioSciences
CDAK
|
76.9 M | $ 0.06 | -55.98 % | $ 2.15 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
142 M | $ 8.37 | - | $ 401 M | USA |
 |
AIkido Pharma
AIKI
|
4.08 M | $ 3.17 | 1.93 % | $ 17.4 M | USA |
 |
Calithera Biosciences
CALA
|
59.5 M | $ 0.37 | -10.95 % | $ 876 K | USA |
 |
Ocular Therapeutix
OCUL
|
392 M | $ 11.53 | -0.17 % | $ 1.82 B | USA |
 |
Forma Therapeutics Holdings
FMTX
|
77.4 M | $ 20.01 | - | $ 958 M | USA |
 |
Oragenics
OGEN
|
3.48 M | $ 1.29 | -2.27 % | $ 2.9 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
220 M | $ 49.55 | -6.81 % | $ 3.04 B | USA |
 |
Oncolytics Biotech
ONCY
|
15.9 M | $ 1.22 | 0.83 % | $ 115 M | Canada |